Hepatocellular carcinoma
Conditions
Interventions
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Primary liver cancer that strictly complies with the clinical diagnostic criteria of the "Standards for the Diagnosis and Treatment of Primary Liver Cancer" or is confirmed by histopathological examination; 2. Aged >= 18 years old, male or female; 3. ECOG PS <= 2; 4. BCLC stage: B or C; 5. Expecting life survival of more than 3 months; 6. Planned on Camrelizumab alone or in combination with other treatment; 7. Patient voluntarily joined the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Women during pregnancy or breastfeeding; 2. Patients with mixed liver cancer(HCC-ICC), second primary tumors; 3. HBV-DNA of subjects with chronic HBV infection must < 2000 IU/ mL; 4. Allergic to Camrelizumab and/or ingredients; 5. Patients with active autoimmune disease or history of autoimmune disease; 6. Patients have received organ transplantation or stem cell transplantation; 7. Severe allergic reactions to other monoclonal antibodies; 8. Patients with active bleeding; 9. Patients with the gastrointestinal ulcer, intestinal perforation or intestinal obstruction; 10. Patients with severe liver, kidney dysfunction(grade 4); 11. According to the judgment of the investigator, there are other serious harm to the safety of the patient or concomitant diseases that affect the completion of the study; 12. Patients who participate in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease control rate;Objective response rate;Drug-related adverse reactions and serious adverse events and specific adverse reactions of these drugs; | — |
Countries
China
Contacts
Public ContactZeng Yong
West China Hospital of Sichuan University
Outcome results
None listed